UW researchers join study of oral MS drug

The UW is participating in the Coral study, for people living with relapsing-remitting multiple sclerosis. The Coral study is the first global clinical study for an oral MS therapy, and the largest effort ever conducted for people with the disease.

Swedish Medical Center is also participating in the Coral study.

The purpose of the study is to assess the efficacy, safety and tolerability of Copaxone, which is administered orally to people with relapsing-remitting MS. The study will include the use of a placebo in some subjects. Enrollment is expected to last at least three months.

People interested in participating can contact researchers at the UW by calling (206) 616-UWMS (8967). ¶